Answers are grounded in this paper and cite their sources.
Research protocol demonstrates plans to assess trial generalizability in metastatic prostate cancer, highlighting disparities between trial participants and real-world clinical populations.
Metastatic prostate cancer (PCa) constitutes ~5% of all new PCa diagnoses in Western countries. For most cases, primary consideration should be given to systemic therapies as the first-line approach based on evidence from randomized controlled trials (RCTs). Despite the importance of RCTs as the pinnacle of evidence in modern medicine, concerns have been raised about their applicability to real-life scenarios. These trials often feature participants who are younger with better performance statuses and prognoses compared to their real-world counterparts. The PIONEER project falls under the Innovative Medicine Initiative's (IMI) "Big Data for Better Outcomes" initiative, aimed at revolutionizing PCa care in Europe. The central focus lies in improving cancer-related outcomes, enhancing health system efficiency, and elevating the quality of health and social care. This study endeavours to evaluate the generalizability of RCT findings concerning newly diagnosed metastatic PCa.
No takes yet. Share an insight, caveat, or question.
Gandaglia et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: